Endocrine Abstracts

Materials and methods: 157 patients (118 women and 39 men) aged from 30 to 73 years with radical treatment for Graves’ disease were included in this study. The patients were divided into two groups depending: (76) included patients with low-normal level of TSH (0.4–2.0 mU/ml), the second group (81 patients) with upper-normal level of TSH 2.1–4.0 mU/ml. Quality of life was assessed with the help of the questionnaire Short-Form SF-36.

Results: In the first group the median follow- up after treatment 7 years (min 7; max 10), the median activity 9.7 mKu (min 4.0; max 18.6) the average level of TSH 1.07 mU/ml (0.4–1.37), a median dose of L-T₄ 75 μg (min 50; max 100).

In the second group, the median follow-up after treatment of 8 years (min 7; max 10), the median activity 6.0 mKu (min 1.1; max 18.9), the average level of TSH 2.89 mU/ml (2.59–3.74), a median dose of L-T₄ 75 μg (min 50; max 100).

In the evaluation of mean values of the quality of life in the first and second group, statistically significant differences were observed in the two indicators: physical functioning and general health were higher in group 1 (P=0.01 and 0.05), all other indicators on eight scales questionnaires were at a level above the average and between the groups did not differ.

Conclusions: The average quality of life of patients were on average and high level, however, there are significant differences in the quality of life among patients with upper- and low-normal TSH. It is established that patients with upper-normal TSH had the worst performance, in the course of our study revealed a statistically significant difference between multiple scales, such as physical functioning, the general state of health.